ArticleTurkish journal of haematology : official journal of Turkish Society of Haematology2026
Clinical Phenotypes and Glycopeptide Escalation Patterns in Pediatric Febrile Neutropenia: Associations with Short-Term Outcomes and Acute Kidney Injury Risk
Article in Turkish journal of haematology : official journal of Turkish Society of Haematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Interpreting Glycopeptide Escalation and Acute Kidney Injury with CautionTurkish journal of haematology : official journal of Turkish Society of Haematology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Febrile neutropenia (FN) in pediatric oncology is a clinically heterogeneous syndrome in which early antibiotic escalation decisions are frequently driven by non-specific severity cues. We aimed to identify baseline clinical phenotypes of pediatric FN, to describe early glycopeptide escalation patterns across these phenotypes, and to examine their associations with short-term outcomes and acute kidney injury (AKI). Materials and Methods: We conducted a retrospective cohort study including 106 FN episodes experienced by 82 pediatric oncology patients initially treated with piperacillin-tazobactam monotherapy. Baseline clinical and laboratory variables available within the first 6 hours of FN onset were used for unsupervised k-means clustering to derive latent clinical phenotypes. Early glycopeptide escalation was defined as the initiation of vancomycin or teicoplanin within 48 hours. Associations with clinical outcomes on day 7 and AKI were evaluated using multivariable cluster-robust regression and inverse probability of treatment weighting. Results: Three distinct FN phenotypes were identified: a high-inflammatory/mucositis-dominant phenotype (39.6%), a hemodynamically severe phenotype (22.6%), and a lower-severity phenotype (37.7%). Early glycopeptide escalation occurred in 26.4% of episodes and was disproportionately concentrated in the high-inflammatory and hemodynamically severe phenotypes. AKI developed in 10.4% of FN episodes and clustered predominantly within escalation-prone phenotypes. After adjustment, early escalation was not associated with improved day-7 clinical success but was associated with a higher observed risk of AKI. Conclusion: Pediatric FN comprises distinct clinical phenotypes that differentially drive antibiotic escalation behavior and renal injury risk. A phenotype-informed approach may help to optimize escalation decisions and potentially reduce preventable toxicity. However, given the observational design of this study, these associations should be interpreted with caution.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.